SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-010655
Filing Date
2023-04-19
Accepted
2023-04-19 17:05:50
Documents
15
Period of Report
2023-04-18
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sabs20230418_8k.htm   iXBRL 8-K 31873
2 EXHIBIT 99.1 ex_502136.htm EX-99.1 16548
7 header.jpg GRAPHIC 16028
  Complete submission text file 0001437749-23-010655.txt   232738

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sabs-20230418.xsd EX-101.SCH 4177
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sabs-20230418_def.xml EX-101.DEF 14103
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sabs-20230418_lab.xml EX-101.LAB 18628
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sabs-20230418_pre.xml EX-101.PRE 14125
9 EXTRACTED XBRL INSTANCE DOCUMENT sabs20230418_8k_htm.xml XML 4820
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 23830654
SIC: 2836 Biological Products, (No Diagnostic Substances)